Literature DB >> 15894676

Interactions of peroxisome proliferator-activated receptor {gamma} and diet in etiology of colorectal cancer.

Maureen A Murtaugh1, Khe-Ni Ma, Bette J Caan, Carol Sweeney, Roger Wolff, Wade S Samowitz, John D Potter, Martha L Slattery.   

Abstract

The peroxisome proliferator-activated receptor gamma (PPARgamma) is one of a group of ligand-activated nuclear receptors responsible for regulation of glucose, lipid homeostasis, cell differentiation, and apoptosis. The 12 proline-to-alanine (Pro12Ala) substitution polymorphism in PPARgamma produces proteins with lower activity. Variation in PPARgamma expression in the bowel and the role of dietary fatty acids as ligands for PPARgamma led investigation of whether the associations of diet with colon and rectal cancer risk were modified by PPARgamma genotype. Data (diet, lifestyle, and DNA) came from case-control studies of colon (1,577 cases and 1,971 controls) and rectal cancer (794 cases and 1,001 controls) conducted in Northern California, Utah, and the Twin City, Minnesota Metropolitan area (colon cancer study only). Unconditional logistic regression models were adjusted for age at selection, body mass index, physical activity, energy intake, dietary fiber, and calcium. We found no significant interactions between macronutrient (fat, protein, and carbohydrate) and colorectal cancer. High lutein intake [odds ratio (OR), 0.63; 95% confidence interval (95% CI), 0.44-0.89], low refined grain intake (OR, 0.70; 95% CI, 0.53-0.94), or a high prudent diet score (OR, 0.66; 95% CI, 0.49-0.89) and PA/AA PPARgamma genotype were associated with reduced colon cancer risk. Risk of rectal cancer was increased among those with the PA/AA PPARgamma genotype and a high mutagen index (OR, 1.63; 95% CI, 1.12, 2.36). Its unclear whether the alterations in risk in those with the less active phenotype for PPARgamma is related to activation of PPARgamma by nutrients or dietary patterns acting as ligands or direct influences of these nutrients on colon and rectal cancer processes that are important with lower PPARgamma activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15894676     DOI: 10.1158/1055-9965.EPI-04-0681

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  16 in total

1.  Loss of JNK2 increases intestinal tumor susceptibility in Apc1638+/- mice with dietary modulation.

Authors:  Xiuli Bi; Nicole M Pohl; Zhinan Yin; Wancai Yang
Journal:  Carcinogenesis       Date:  2010-12-23       Impact factor: 4.944

2.  Peroxisome proliferator-activated receptor-γ (PPARγ) Pro12Ala polymorphism and colorectal cancer (CRC) risk.

Authors:  Wei Wang; Yan Shao; Shenhua Tang; Xianyong Cheng; Haifeng Lian; Chengyong Qin
Journal:  Int J Clin Exp Med       Date:  2015-03-15

3.  Peroxisome proliferator-activated receptor-gamma 34C>G polymorphism and colorectal cancer risk: a meta-analysis.

Authors:  Yong-Liang Lu; Gai-Ling Li; Hui-Lian Huang; Jing Zhong; Li-Cheng Dai
Journal:  World J Gastroenterol       Date:  2010-05-07       Impact factor: 5.742

4.  Association between six genetic polymorphisms and colorectal cancer: a meta-analysis.

Authors:  Cheng Chen; Lingyan Wang; Qi Liao; Leiting Xu; Yi Huang; Cheng Zhang; Huadan Ye; Xuting Xu; Meng Ye; Shiwei Duan
Journal:  Genet Test Mol Biomarkers       Date:  2014-02-19

5.  Genetic polymorphisms in fatty acid metabolism genes and colorectal cancer.

Authors:  M Crous-Bou; G Rennert; R Salazar; F Rodriguez-Moranta; H S Rennert; F Lejbkowicz; L Kopelovich; S M Lipkin; S B Gruber; V Moreno
Journal:  Mutagenesis       Date:  2012-03       Impact factor: 3.000

6.  Influence of peroxisome proliferator-activated receptor (PPAR)gamma Plo12Ala polymorphism as a shared risk marker for both gastric cancer and impaired fasting glucose (IFG) in Japanese.

Authors:  Tomomitsu Tahara; Tomiyasu Arisawa; Tomoyuki Shibata; Masakatsu Nakamura; Fangyu Wang; Naoko Maruyama; Yoshio Kamiya; Masahiko Nakamura; Hiroshi Fujita; Mitsuo Nagasaka; Masami Iwata; Kazuya Takahama; Makoto Watanabe; Ichiro Hirata; Hiroshi Nakano
Journal:  Dig Dis Sci       Date:  2007-09-01       Impact factor: 3.199

7.  Genetic variation in the inflammation and innate immunity pathways and colorectal cancer risk.

Authors:  Hansong Wang; Darin Taverna; Daniel O Stram; Barbara K Fortini; Iona Cheng; Lynne R Wilkens; Terrilea Burnett; Karen W Makar; Noralane M Lindor; John L Hopper; Steve Gallinger; John A Baron; Robert Haile; Laurence N Kolonel; Brian E Henderson; Polly A Newcomb; Graham Casey; David Duggan; Cornelia M Ulrich; Loïc Le Marchand
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-09-17       Impact factor: 4.254

8.  Peroxisome proliferator activated receptor gamma in colonic epithelial cells protects against experimental inflammatory bowel disease.

Authors:  M Adachi; R Kurotani; K Morimura; Y Shah; M Sanford; B B Madison; D L Gumucio; H E Marin; J M Peters; H A Young; F J Gonzalez
Journal:  Gut       Date:  2006-03-17       Impact factor: 23.059

Review 9.  Bioactive food components, inflammatory targets, and cancer prevention.

Authors:  Young S Kim; Matthew R Young; Gerd Bobe; Nancy H Colburn; John A Milner
Journal:  Cancer Prev Res (Phila)       Date:  2009-03-03

10.  Peroxisome proliferator-activated receptor gamma (PPARG) rs1801282 C>G polymorphism is associated with cancer susceptibility in asians: an updated meta-analysis.

Authors:  Yafeng Wang; Yu Chen; Heping Jiang; Weifeng Tang; Mingqiang Kang; Tianyun Liu; Zengqing Guo; Zhiqiang Ma
Journal:  Int J Clin Exp Med       Date:  2015-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.